Allogene Therapeutics (ALLO) Current Assets: 2019-2025
Historic Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $260.7 million.
- Allogene Therapeutics' Current Assets fell 14.35% to $260.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.7 million, marking a year-over-year decrease of 14.35%. This contributed to the annual value of $303.4 million for FY2024, which is 33.92% down from last year.
- As of Q3 2025, Allogene Therapeutics' Current Assets stood at $260.7 million, which was down 7.76% from $282.7 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Current Assets peaked at $716.1 million during Q1 2021, and registered a low of $260.7 million during Q3 2025.
- Its 3-year average for Current Assets is $382.9 million, with a median of $395.4 million in 2024.
- The largest annual percentage gain for Allogene Therapeutics' Current Assets in the last 5 years was 41.96% (2021), contrasted with its biggest fall of 44.23% (2021).
- Quarterly analysis of 5 years shows Allogene Therapeutics' Current Assets stood at $471.3 million in 2021, then increased by 12.20% to $528.8 million in 2022, then decreased by 13.18% to $459.1 million in 2023, then plummeted by 33.92% to $303.4 million in 2024, then decreased by 14.35% to $260.7 million in 2025.
- Its Current Assets stands at $260.7 million for Q3 2025, versus $282.7 million for Q2 2025 and $291.6 million for Q1 2025.